Caixa leads €1.6m round for Minoryx

The investment will finance studies into potential drugs for the treatment of adrenoleukodystrophy, a disease that targets the nervous system and adrenal glands.

Swiss charity Sanfilippo Foundation also took part in the round.

Caixa's investment was drawn from Caixa Innvierte BioMed II, which launched in March 2014 with a €35m target. The vehicle's maiden investment saw Caixa join CRB Inverbio in a €3m round for wearable medical technology company Nuubo.

Company
Founded in 2011 and headquartered in Mataró, near Barcelona, Minoryx produces drugs for patients suffering from genetic diseases that target the central nervous system.

People
Daniel Blach, a partner on the venture team at Sanfilippo Foundation, has taken a seat on the board. Nigel Ten Fleming is chairman of Minoryx and Marc Martinell is CEO.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Spain
• Caixa Capital Risc